TrialHaematologica2025

Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study.

Muhit Özcan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.